Chiang Li

905 total citations
52 papers, 795 citations indexed

About

Chiang Li is a scholar working on Oncology, Toxicology and Molecular Biology. According to data from OpenAlex, Chiang Li has authored 52 papers receiving a total of 795 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Oncology, 18 papers in Toxicology and 17 papers in Molecular Biology. Recurrent topics in Chiang Li's work include Bioactive Compounds and Antitumor Agents (18 papers), Cancer Cells and Metastasis (11 papers) and Cancer Mechanisms and Therapy (8 papers). Chiang Li is often cited by papers focused on Bioactive Compounds and Antitumor Agents (18 papers), Cancer Cells and Metastasis (11 papers) and Cancer Mechanisms and Therapy (8 papers). Chiang Li collaborates with scholars based in United States, Canada and Australia. Chiang Li's co-authors include Arthur B. Pardee, You Li, Bruce D. James, Robert J. Magee, Linna Ding, Laura Borodyansky, Shireen Anne Nah, David I. Cohen, Matthew Hitron and Yunzhen Cao and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and Cancer Research.

In The Last Decade

Chiang Li

51 papers receiving 780 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Chiang Li United States	16	329	255	245	109	97	52	795
Claudéte J. Valduga Brazil	16	443 1.3×	112 0.4×	88 0.4×	256 2.3×	154 1.6×	28	1.2k
Hiroshi Kuga Japan	14	840 2.6×	676 2.7×	104 0.4×	146 1.3×	63 0.6×	28	1.3k
Dipon Das India	22	561 1.7×	297 1.2×	45 0.2×	178 1.6×	43 0.4×	31	1.1k
Satyakam Singh United States	20	571 1.7×	718 2.8×	32 0.1×	176 1.6×	105 1.1×	27	1.2k
Shigenori Ohta Japan	22	771 2.3×	143 0.6×	110 0.4×	151 1.4×	32 0.3×	41	1.4k
Vivek K. Kashyap United States	21	443 1.3×	209 0.8×	19 0.1×	128 1.2×	37 0.4×	49	961
Indu Sinha United States	14	270 0.8×	145 0.6×	30 0.1×	32 0.3×	18 0.2×	24	751
Shun‐ichi Ikeda Japan	14	241 0.7×	273 1.1×	28 0.1×	138 1.3×	97 1.0×	55	816
Janet S. Macpherson United Kingdom	16	385 1.2×	333 1.3×	50 0.2×	119 1.1×	98 1.0×	30	861
Zhaoshi Bai China	15	310 0.9×	120 0.5×	91 0.4×	313 2.9×	27 0.3×	30	818

Countries citing papers authored by Chiang Li

Since Specialization

Citations

This map shows the geographic impact of Chiang Li's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chiang Li with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chiang Li more than expected).

Fields of papers citing papers by Chiang Li

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chiang Li. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chiang Li. The network helps show where Chiang Li may publish in the future.

Co-authorship network of co-authors of Chiang Li

This figure shows the co-authorship network connecting the top 25 collaborators of Chiang Li. A scholar is included among the top collaborators of Chiang Li based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chiang Li. Chiang Li is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Shah, Manish A., Kohei Shitara, Florian Lordick, et al.. (2018). The BRIGHTER trial: A phase 3 randomized double-blind study of napabucasin (NAPA) plus paclitaxel (PTX) versus placebo (PBO) plus PTX in patients (pts) with pretreated advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma.. Journal of Clinical Oncology. 36(15_suppl). 4010–4010. 20 indexed citations

Edenfield, William J., Carlos Becerra, Fadi S. Braiteh, et al.. (2017). A phase Ib study of napabucasin plus weekly paclitaxel in patients with advanced melanoma.. Journal of Clinical Oncology. 35(15_suppl). 9553–9553. 4 indexed citations

Coté, Gregory A., William J. Edenfield, Scott A. Laurie, et al.. (2017). A phase 1b/2 study of amcasertib, a first-in-class cancer stemness kinase inhibitor, in advanced adenoid cystic carcinoma.. Journal of Clinical Oncology. 35(15_suppl). 6036–6036. 6 indexed citations

Bendell, Johanna C., Bert H. O’Neil, Alexander Starodub, et al.. (2017). Cancer stemness inhibition and chemosensitization: Phase 1b/II study of cancer stemness inhibitor napabucasin (BBI-608) with FOLFIRI +/- bevacizumab (Bev) administered to colorectal cancer (CRC) patients (pts).. Journal of Clinical Oncology. 35(4_suppl). 593–593. 11 indexed citations

Grothey, Axel, Manish A. Shah, Takayuki Yoshino, et al.. (2017). CanStem303C trial: A phase III study of napabucasin (BBI-608) in combination with 5-fluorouracil (5-FU), leucovorin, irinotecan (FOLFIRI) in adult patients with previously treated metastatic colorectal cancer (mCRC).. Journal of Clinical Oncology. 35(15_suppl). TPS3619–TPS3619. 16 indexed citations

Bendell, Johanna C., Joleen M. Hubbard, Bert H. O’Neil, et al.. (2017). Phase 1b/II study of cancer stemness inhibitor napabucasin (BBI-608) in combination with FOLFIRI +/- bevacizumab (bev) in metastatic colorectal cancer (mCRC) patients (pts).. Journal of Clinical Oncology. 35(15_suppl). 3529–3529. 12 indexed citations

Edenfield, William J., Carlos Becerra, Adrian Langleben, et al.. (2017). A phase 2 study of napabucasin with weekly paclitaxel in previously treated metastatic breast cancer.. Journal of Clinical Oncology. 35(15_suppl). 1084–1084. 3 indexed citations

Coté, Gregory M., Nicole G. Chau, Alexander I. Spira, et al.. (2017). A phase 1b/2 study of amcasertib, a first-in-class cancer stemness kinase inhibitor in advanced head and neck cancer.. Journal of Clinical Oncology. 35(15_suppl). 6032–6032. 2 indexed citations

Bekaii‐Saab, Tanios, Chung‐Pin Li, Takuji Okusaka, et al.. (2017). CanStem111P trial: A phase III study of napabucasin (BBI-608) plus nab-paclitaxel (nab-PTX) with gemcitabine (gem) in adult patients with metastatic pancreatic adenocarcinoma (mPDAC).. Journal of Clinical Oncology. 35(15_suppl). TPS4148–TPS4148. 11 indexed citations

10.

Shahda, Safi, Bassel F. El‐Rayes, Bert H. O’Neil, et al.. (2016). A phase Ib study of cancer stem cell (CSC) pathway inhibitor BBI-608 in combination with gemcitabine and nab-paclitaxel (nab-PTX) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC).. Journal of Clinical Oncology. 34(4_suppl). 284–284. 6 indexed citations

11.

Bekaii‐Saab, Tanios, Sameh Mikhail, Adrian Langleben, et al.. (2016). A phase Ib/II study of BBI608 combined with weekly paclitaxel in advanced pancreatic cancer.. Journal of Clinical Oncology. 34(4_suppl). 196–196. 9 indexed citations

12.

Becerra, Carlos, Joe Stephenson, Derek J. Jonker, et al.. (2015). Phase Ib/II study of cancer stem cell (CSC) inhibitor BBI608 combined with paclitaxel in advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma.. Journal of Clinical Oncology. 33(15_suppl). 4069–4069. 24 indexed citations

13.

Hubbard, Joleen M., Derek J. Jonker, Bert H. O’Neil, et al.. (2015). A phase Ib study of BBI608 in combination with FOLFIRI with and without bevacizumab in patients (pts) with advanced colorectal cancer (CRC).. Journal of Clinical Oncology. 33(15_suppl). 3616–3616.

14.

Sajeesh, S., Sun Woo Hong, Soohyun Kim, et al.. (2014). Efficient intracellular delivery and multiple-target gene silencing triggered by tripodal RNA based nanoparticles: A promising approach in liver-specific RNAi delivery. Journal of Controlled Release. 196. 28–36. 28 indexed citations

15.

Jeay, Sébastien, Neru Munshi, Jason E. Hill, et al.. (2007). ARQ 197, a highly selective small molecule inhibitor of c-Met, with selective antitumor properties in a broad spectrum of human cancer cells. Cancer Research. 67. 2369–2369. 17 indexed citations

16.

Anderson, K. C., Chiang Li, Jodie E. Moreau, Thomas Chan, & Michael Rosenblatt. (2007). ARQ 197, a small molecule inhibitor of c-met, prevents bone metastasis in a humanized mouse model of breast cancer. Molecular Cancer Therapeutics. 6. 7 indexed citations

17.

Pardee, Arthur B., You Li, & Chiang Li. (2002). Cancer Therapy with ß-Lapachone. Current Cancer Drug Targets. 2(3). 227–242. 187 indexed citations

18.

Cohen, Sandra, Chiang Li, Linna Ding, et al.. (1999). Pronounced acute immunosuppression in vivo mediated by HIV Tat challenge. Proceedings of the National Academy of Sciences. 96(19). 10842–10847. 82 indexed citations

19.

Li, Chiang, et al.. (1991). A convenient method using methanol/benzyltrialkylammonium reagents for simultaneous extraction and methylation of 2,4-dichlorophenoxyacetic acid in soil, with subsequent analysis via gas chromatography. Journal of Agricultural and Food Chemistry. 39(6). 1110–1112. 4 indexed citations

20.

Li, Chiang, Bruce D. James, & Robert J. Magee. (1989). Adsorptive stripping voltammetry of some trace elements in biological samples, II: Nickel, arsenic, aluminium and selenium. Microchimica Acta. 98(4-6). 149–156. 24 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact